Factors predictive of virological failure on atazanavir in 310 HIV-infected patients-Reference-Cited by-同舟云学术

Factors predictive of virological failure on atazanavir in 310 HIV-infected patients

Published:2010-06-19 Issue:10 Volume:24 Page:1593-1595
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Lescure François-Xavier,Poirier Jean-Marie,Meynard Jean-Luc,Guiard-Schmid Jean-Baptiste,Zouai Ouahiba,Bonnard Philippe,Slama Laurence,Amiel Corinne,Girard Pierre-Marie,Pialoux Gilles

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference11 articles.

1. 96-week comparison of once-daily ATV/RTV and twice-daily lopinavir/RTV in patients with multiple virologic failures;Johnson;AIDS,2006

2. ATV plus RTV or saquinavir, and lopinavir/RTV in patients experiencing multiple virological failures;Johnson;AIDS,2005

3. Comparison of ATV with lopinavir/RTV in patients with prior protease inhibitor failure: a randomized multinational trial;Cohen;Curr Med Res Opin,2005

4. Comparison of once-daily ATV with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV;Squires;J Acquir Immune Defic Syndr,2004

5. Effects of ATV/RTV and lopinavir/RTV on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically;Noor;AIDS,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV;Therapeutic Drug Monitoring;2019-08

2. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial);Journal of Antimicrobial Chemotherapy;2016-04-10

3. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study);Journal of Antimicrobial Chemotherapy;2015-07-14

4. Efficacy, Tolerability and Virological Consequences of Long-Term Use of Unboosted Atazanavir Plus 2 NRTIs in HIV-Infected Patients;Current HIV Research;2014-11-21

5. A Maintenance Dose of Atazanavir/Ritonavir 200/100 mg Once Daily Is Effective in Virologically Suppressed HIV-1–Infected Patients;JAIDS Journal of Acquired Immune Deficiency Syndromes;2013-06-01